AI has the potential to revolutionise the pharmaceuticals industry. Key considerations include how to monetise these innovations and what types of IP protection are available for AI-influenced drug discoveries?
Topic: RegulationSubscribe to Regulation
Maximising the benefits of AI – supra-national considerations
A recent EC draft guidance document on a European approach to AI surveys the opportunities stemming from the use of AI for the European industry and the potential socio-economic impact of AI on EU citizens.
Free movement of algorithms within the EU
Freedom of establishment will allow artificial intelligence with legal personality to move freely and be recognised within the EU single market.
Artificial intelligence routed to gain juristic personality (Estonia)
Estonia may become the first country in the world to grant AI some form of juristic personality, giving robots personal rights and responsibilities. Read more >
The House of Lords Select Committee on Artificial Intelligence publishes responses to call for evidence
Companies and industry experts respond to public call for evidence on AI.Read more >